# Healthcare resource use in myasthenia gravis: a United States health claims analysis

# Author list, affiliations and degree information

Milada Mahic PhD1,\*, Ali Bozorg MD, MBA2, Jan Rudnik PhD3, Piotr Zaremba MSc4, Anna Scowcroft MSc1

1UCB Pharma, Slough, United Kingdom; 2UCB Pharma, Morrisville, NC, United States; 3UCB Pharma, Warszawa, Poland; 4UCB Pharma, Katowice, Poland

\*At time of study.

# Corresponding author

Anna Scowcroft MSc, ([Anna.Scowcroft@ucb.com](mailto:Anna.Scowcroft@ucb.com)), UCB Pharma, 208 Bath Road, Slough, SL1 3WE, UK

# Appendix

### Appendix Table 1: Measures and definitions

|  |  |
| --- | --- |
| **Outcome** | **Definition** |
| **Serious MG exacerbation** | Occurrence of Ig (SC or IV) cycle, PLEX cycle, or MG-related hospitalization, or ER visit with MG diagnosis. In the event that a patient is treated with Ig and/or PLEX while in hospital, this will count as only one occurrence of exacerbation |
| **Myasthenic crisis** | Occurrence of IVIg/PLEX treatment AND MG diagnosis AND respiratory failure or mechanical ventilation in an inpatient setting. All three events need to occur within 7 days |
| **Ig (IV/SC) cycle** | Ig therapy at least 7 days after last Ig therapy is considered the start of a new cycle. Includes both IV and SC administration |
| **PLEX cycle** | PLEX therapy after a gap of at least 7 days since last PLEX therapy is considered the start of a new cycle |
| **Event rate** | Mean number of events per patients divided by follow-up time among patients with at least one event |

Ig, immunoglobulin; IV, intravenous; MG, myasthenia gravis; PLEX, plasma exchange; SC, subcutaneous.